✦ LIBER ✦

CI-911: A placebo-controlled study in patients with primary degenerative dementia

✍ Scribed by Maurice W. Dysken; Susan Anton-Johnson; Linda Klein; Michael Kuskowski; Lawrence J. Schut; Steven H. Miles; Gabe J. Maletta; Richard De Jong

Publisher: John Wiley and Sons
Year: 1988
Tongue: English
Weight: 258 KB
Volume: 12
Category: Article
ISSN: 0272-4391
DOI: 10.1002/ddr.430120309

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Modafinil treatment of fatigue in patien

Modafinil treatment of fatigue in patients with ALS: A placebo-controlled study

✍ Judith G. Rabkin; Paul H. Gordon; Martin McElhiney; Richard Rabkin; Sheena Chew; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 1 views

Sodium valproate in the treatment of agg

Sodium valproate in the treatment of aggressive behavior in patients with dementia—a randomized placebo controlled clinical trial

✍ Rob C. Sival; P. M. Judith Haffmans; Paul A. F. Jansen; Sijmen A. Duursma; Piet 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 3 views

## Objectives: The efficacy and tolerability of sodium valproate 2 x 240 mg compared to placebo were investigated in aggressive behavior in dementia. ## Design: A randomized, placebo controlled, double-blind cross-over design. the trial included a baseline period (one week); a placebo period (thr

Cholangiocarcinoma in patients with prim

Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study

✍ Naga Chalasani; Arthur Baluyut; Ayaaz Ismail; Atif Zaman; Gagan Sood; Reem Ghali 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

Randomized double-blind placebo-controll

Randomized double-blind placebo-controlled crossover study of caffeine in patients with intermittent claudication

✍ A. H. Momsen; M. B. Jensen; C. B. Norager; M. R. Madsen; T. Vestersgaard-Anderse 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 2 views

Rituximab in patients with primary progr

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro

Use of alternative therapies in patients

Use of alternative therapies in patients with dementia and mild cognitive impairment: a prospective, controlled study

✍ Julia Landin; Lutz Frölich; Stefan Schwarz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB 👁 1 views

## Abstract ## Objectives To study the frequency and type of alternative therapies used in patients with dementia and Mild Cognitive Impairment. ## Methods In a prospective study, 77 outpatients and 62 healthy volunteers were interviewed using a questionnaire concerning frequency, type and motiv